Nicox’s portfolio includes three programs in development, all of which are in, or preparing to enter, Phase 2 clinical studies: NCX 470 for reduction of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension; NCX 4251 for patients with acute exacerbations of blepharitis; and NCX 4280 (formerly AC-120) for relief of ocular redness and lid swelling due to morning ocular congestion. NCX 470 is based on our proprietary nitric oxide (NO) donating research platform. NCX 4251 and NCX 4280 are product candidates based on repurposed molecules that have previously been used in other indications and therapeutic areas. Our pipeline also includes future generation stand alone NO donors in the research stage and other exploratory novel NO donating compounds targeting ophthalmic conditions including glaucoma and ocular hypertension. In addition, we have two ophthalmology assets that have been approved by the U.S. Food and Drug Administration, or FDA, VYZULTATM (latanoprostene bunod ophthalmic solution), 0.024% and ZERVIATETM (cetirizine ophthalmic solution), 0.24%, formerly AC 170. VYZULTA, indicated for the reduction of IOP in patients with open angle glaucoma or ocular hypertension, is exclusively licensed worldwide to Bausch + Lomb, a Bausch Health Companies Inc. company, and has been commercialized by Bausch + Lomb in the United States since December 2017. VYZULTA is the first approved product by the U.S. FDA generated from our proprietary NO donating research platform. ZERVIATE, indicated for the treatment of ocular itching associated with allergic conjunctivitis, has been exclusively licensed in the United States to Eyevance Pharmaceuticals and is planned to be launched in the U.S. by our partner.
The Company’s strategy is to become a fully integrated pharmaceutical company focused on the discovery, development and commercialization of novel ophthalmic therapeutics. This strategy includes the expansion of its ophthalmic product portfolio through internal discovery efforts based on its proprietary NO-donating research platform, the repurposing of well-established molecules, clinically and commercially validated, and possible in-licensing activities or acquisitions of additional ophthalmic product candidates or products. Nicox was formed in 1996 and listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) in 1999. The Company is headquartered in Sophia Antipolis, France, has research facilities in Bresso, Italy, and a U.S. office in Fort Worth, Texas.
Addressing a gap in the ophthalmic market
Certain areas in the ophthalmic market are expected to experience considerable growth due to a significant need for better treatments and diagnostic options. The ophthalmic market is currently dominated by large global pharmaceutical companies and much smaller national players. We see the opportunity for a targeted R&D organisation in ophthalmology. Our experienced team brings together a heritage of scientific, financial, business and corporate development expertise, strengthened by our own in-house research capabilities. Our growth strategy is based on the validated therapeutic effect of our proprietary NO-donating research platform, our other proprietary development assets and our partnered programs. We intend to develop our portfolio through outstanding international collaborations and internal focus on our proprietary developments.
IMS Health Analytics sales 2016
Partnerships accelerate the advancement of Nicox’s research and development activities, allowing us to share and build our expertise and endorse the company’s nitric oxide-donating research platform. The Company expects partnerships to continue to have a significant place in its future development both through the partnering of assets already advanced by Nicox and through allowing us to access innovative science from external sources. We are always interested in hearing about potential collaborations and seek partners with complementary strengths who share our values; do not hesitate to contact us if you share our passion for visible science.
Nicox is led by a team of experienced professionals whose combined expertise covers research, clinical development, regulatory interactions, finance, business and corporate development, alliance management and communication. This experience was acquired in leading pharmaceutical and biotech companies and the team includes Michele Garufi, one of Nicox’s co-founders.
Nicox is proud to present its Board of Directors, whose members are highly experienced in the pharmaceutical and biotech industry.